These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30322468)

  • 1. [Use of dipeptidyl peptidase-4 inhibitors in patients with diabetes].
    Carramiñana Barrera FC
    Semergen; 2018 Jun; 44 Suppl 1():10-17. PubMed ID: 30322468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recommendations of the main clinical practice guidelines].
    Miravet I Jiménez S
    Semergen; 2018 Jun; 44 Suppl 1():3-9. PubMed ID: 30322471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of dipeptidyl peptidase-4 inhibitors in diabetic patients in special situations].
    Seguí Díaz M
    Semergen; 2018 Jun; 44 Suppl 1():18-25. PubMed ID: 30322469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
    Scheen AJ
    Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Effects of Incretin-Based Therapies.
    White WB; Baker WL
    Annu Rev Med; 2016; 67():245-60. PubMed ID: 26768240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cardiovascular safety of non-insulin anti-diabetic drugs. Scientific position statement of SEMERGEN].
    Prieto MÁ; Comas Samper JM; Escobar Cervantes C; Gasull Molinera V
    Semergen; 2014; 40(5):261-73. PubMed ID: 24882393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Incretin mimetic drugs: therapeutic positioning].
    López Simarro F
    Semergen; 2014 Jul; 40 Suppl 2():25-33. PubMed ID: 25311717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
    Gooßen K; Gräber S
    Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular safety of therapies for type 2 diabetes.
    Gupta P; White WB
    Expert Opin Drug Saf; 2017 Jan; 16(1):13-25. PubMed ID: 27652617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus.
    Azim S; Baker WL; White WB
    Curr Cardiol Rep; 2014 Nov; 16(11):541. PubMed ID: 25303895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
    Bonadonna RC; Borghi C; Consoli A; Volpe M
    Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):759-66. PubMed ID: 27373139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety.
    Green JB
    Postgrad Med; 2012 Jul; 124(4):54-61. PubMed ID: 22913894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
    Abel T; Fehér J
    Orv Hetil; 2010 Jun; 151(25):1012-6. PubMed ID: 20519186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
    Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E; Cigolini M
    Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinguishing among incretin-based therapies. Introduction.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S3-4. PubMed ID: 20824238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.